Company Overview
Snapshot
Founded in August 2021 by Zeev Russak and Ofer Peleg, Infiniplex operates with 11–50 employees. The company has secured $1.1 million across one funding round.
Business overview
Infiniplex is a Health Tech & Life Sciences company focused on cancer monitoring and screening. The company develops technology to utilize routine blood testing for screening genetic tumor biomarkers, aiming to provide preemptive, preventive, and follow-up cancer screenings at an accessible and affordable cost. Infiniplex's core product, Chiffon, seeks to identify common and rare cancer types through standard blood tests, leveraging existing laboratory equipment and expertise. It operates within the diagnostics, oncology, and medical technologies sectors, serving the healthcare industry with a B2B business model.
Strategic signal
In May 2022, Infiniplex secured an investment from Terra Venture Partners, indicating early investor confidence in its innovative approach to cancer diagnostics. This funding suggests a positive signal for the company's potential to advance its mission of making cancer screening more accessible and affordable through routine blood tests, positioning it for further development in the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- When was Infiniplex founded?
- Infiniplex was founded in August 2021.
- What is Infiniplex's primary focus?
- Infiniplex focuses on utilizing routine blood testing to screen for genetic tumor biomarkers, aiming to provide preemptive, preventive, and follow-up cancer screenings at an accessible and affordable cost.
- How many employees does Infiniplex have?
- Infiniplex has 11–50 employees.
- What was a significant funding event for Infiniplex?
- In May 2022, Infiniplex secured seed funding of $1.1 million from Terra Venture Partners, marking a key milestone in its development of cancer monitoring and screening technologies.
- What is the total capital raised by Infiniplex?
- Infiniplex has raised a total of $1.1 million across one funding round.